Phase 2 N=13 Intranasal Oxytocin in Hypothalamic Obesity
Craniopharyngioma · Hypothalamic Obesity
Primary: Weight Loss — 88.3; 91.9; 1.2; 0.9 kg — p=0.92
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · Chronic Fatigue Syndrome · Myalgic Encephalomyelitis
Primary: Change in Peak Oxygen Uptake (Peak VO2) Between the First and Second iCPET — 13.3; -40.3; 111.8 mL/min — p=0.043
Phase 2 N=351 Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
Acute Kidney Injury (AKI)
Primary: Percentage of Participants Developing AKI Based on Serum Creatinine (SCr) Criteria Within 72 Hrs From End of Surgery (AKI-SCr72h) — 24.6; 21.0 percentage of participants…
Phase 2 N=7 Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)
Arterial Calcification · CD73 Deficiency
Primary: Ankle-brachial Index at Rest at Pre-treatment, On-treatment and Post-treatment of Etidronate in Participants Diagnosed With ACDC — 0.5741; 0.5411; 0.5222; 0.5266 score…
Phase 2 N=26 Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Lung Cancer · Mesothelioma
Primary: Disease Control Rate at 4 Months — 8 Participants
Phase 2 N=286 A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
Dyslipidemias · Hyperlipidemias · Hyperlipoproteinemias
Primary: Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 — -1.1; -23.5; -23.2; -25.3 Percent change — p=<0.001
Phase 2 N=313 Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
Migraine
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 18; 13; 17; 1 Participants
Phase 2 N=272 A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline to Last Visit of Double-Blind Treatment Period in Cognitive Function as Measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale…
Phase 2 N=190 Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
Vasomotor Symptoms (VMS)
Primary: Percentage of Subjects With Adverse Events — 56.7 percentage of subjects
Phase 2 N=12 A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
Necrobiosis Lipoidica
Primary: Evaluation of Patients With Adverse Events — 10 Participants
Phase 2 N=304 Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
Plaque Psoriasis
Primary: Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale — 107; 10 Participants — p=<0.0001
Phase 2 N=7 A Study to Evaluate Safety of Three Intra-articular Injections of Ampion in the Knee of Adults With Osteoarthritis Pain
Osteoarthritis of the Knee
Primary: Incidence and Severity of Adverse Events and Serious Adverse Events (Phase 1) — 0; 15 events
Phase 2 N=108 Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
Urothelial Carcinoma · Bladder Cancer
Primary: Progression-free Survival (PFS) — 3.0; 5.4 months
Phase 2 N=77 Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
Mild Cognitive Impairment
Primary: Number of Participants With a Hypotensive Episode — 16; 4 Participants
Phase 2 N=22 A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Prostate Cancer · Castration-resistant Prostate Cancer · Castration-resistant Prostate Cancer Metastatic to Bone
Primary: Bone Scan Index — 2.90; 3.79 percentage of skeletal mass